News headlines about Catalyst Pharmaceuticals (NASDAQ:CPRX) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Catalyst Pharmaceuticals earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.3931602342043 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the media headlines that may have effected Accern’s rankings:
- Catalyst Pharmaceuticals Announces Date and Time Change for … – Nasdaq (nasdaq.com)
- Catalyst Pharmaceuticals Announces Date and Time Change for Fourth Quarter and Year-End Financial Results Call … – GlobeNewswire (press release) (globenewswire.com)
- ‘Chamomile Extract Market to Surge at a Robust Pace in Terms of Revenue Over 2022 (openpr.com)
- Carbon Disulfide Market Worth $165.1 Million By 2025 | CAGR: 2.4% : Grand View Research, Inc. (prnewswire.com)
- Catalyst Pharmaceuticals Announces Date and Time Change for Fourth Quarter and Year-End Financial Results Call and Webcast (finance.yahoo.com)
Catalyst Pharmaceuticals (NASDAQ:CPRX) opened at $3.13 on Wednesday. The firm has a market cap of $332.02, a price-to-earnings ratio of -14.90 and a beta of 1.41. Catalyst Pharmaceuticals has a 52-week low of $1.12 and a 52-week high of $4.51.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.